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Branched chain fatty acids (BCFAs) are a class of fatty acid with promising anticancer activity. 
The BCFA 13-methyltetradecanoic acid (13-MTD) inhibits tumour growth in vivo without 
toxicity but efficacy is limited by moderate potency, a property shared by all known BCFAs. 
The mechanism of action of BCFAs has not been fully elucidated, and in the absence of a 
clearly defined target optimisation of BCFA potency must rely on structure-activity 
relationships. Our current understanding of the structural features that promote BCFA 
anticancer activity is limited by the low structural diversity of reported BCFAs. The aim of this 
study was to examine the effects of two new structural modifications- unsaturation and 
branching group size- on BCFA activity. Thus, homologous series of saturated and cis-Δ9 
unsaturated BCFAs were synthesised bearing methyl, ethyl, propyl and butyl branching 
groups, and were screened in vitro for activity against three human cancer cell lines. Potencies 
of the new BCFAs were compared to 13-MTD and  an unbranched monounstaurated fatty acid 
(MUFA) bearing a cis-Δ9 double bond. The principal findings to emerge were that the 
anticancer activity of BCFAs was adversly affected by larger branching groups but 
significantly improved by incorporation of a cis-Δ11 double bond into the BCFA alkyl chain. 
This study provides new structure-activity relationship insights that may be used to develop 




Breast cancer is the second leading cause of cancer-relates deaths in women, and there 
is a critical need to develop novel anticancer drugs to treat cancers that are refractory to 
established anticancer agents. Accumulating evidence suggests that lipids and fatty acids 
possess anticancer actions that can be harnessed to develop new drugs to inhibit tumour growth, 
and drug design strategies to overcome their challenging physicochemical properties have 
yielded clinically approved drugs (Collins et al., 1993; Murray et al., 2014; Murray et al.,  2015; 
Van & Verheij, 2013). Thus, lipids and fatty acids are viable lead compounds for cancer drug 
development. 
Branched chain fatty acids (BCFAs) are a naturally occurring class of fatty acids with 
anticancer actions. The widely studied BCFA, 13-methyltetradecanoic acid (13-MTD, Fig. 1), 
is an iso-C15 branched chain fatty acid that was first isolated from a fermented soy bean product 
marketed as a nutritional and therapeutic supplement. In cell-based studies 13-MTD inhibited 
proliferation and induced apoptosis in several human cancer cell lines, including breast (MCF-
7, SK-BR-3), bladder (T24, 5637), prostate (DU-145), colon (HCT-116), liver (SNU-423, LCI-
D35), lymphatic (Jurkat, EL4) and pancreatic (BxPC-3) cancer with IC50 values ranging from 
26 – 159 µM (Cai et al., 2013; Lin et al., 2012; Shioiri et al., 1998; Wongtangtintharn et al., 
2005; Wongtangtintharn et al., 2004; Yang et al., 2000). 13-MTD is well tolerated by mice and 
oral delivery of 13-MTD (35-70 mg/kg/day) inhibited tumour growth in mice carrying DU 145, 
LCI-D35, and Jurkat xenografts (Cai et al., 2013; Yang et al., 2000). The naturally occurring 
anteiso-C15 analogue of 13-MTD, 12-methyltetradecanoic acid (12-MTA), has also been 
shown to inhibit proliferation of several cancer cell lines, including prostate (DU145, PC3), 
lung (H1299, A549) and breast cancer (MCF-7), with IC50 values ranging from 71 – 146 µM, 
and like 13-MTD, reduced tumour growth in vivo without any apparent toxicity (Murray et al., 
2014; Wongtangtintharn et al., 2004; Wright et al, 2005; Yang et al., 2003).  
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Although 13-MTD and 12-MTA possess promising in vivo activity, moderate potency 
limits their efficacy and therapeutic potential. Medicinal chemistry-based approaches to 
improve drug potency typically involve understanding the steric and electronic factors that 
govern the interaction of a drug with its cellular target. Several studies of 13-MTD have 
identified possible mechanisms of action such as disruption of mitochondrial integrity, 
membrane fluidity, and fatty acid biosynthesis (Cai et al., 2013; Lin et al., 2012; 
Wongtangtintharn et al., 2006; Wongtangtintharn et al., 2005; Yang et al., 2000), however the 
precise cellular target of 13-MTD remains unknown. In the absence of a defined target, a 
ligand-based approach to improve BCFA anticancer activity must be undertaken, which 
involves the development of a structure-activity relationship (SAR) that describes how drug 
activity is affected by structural modifications. 
Some SAR insights on the BCFA scaffold have emerged. A series of C12-20 iso-BCFAs, 
which are structural analogues of 13-MTD but with elongated or contracted alkyl chains, were 
assess for activity against MCF-7 breast cancer cells. The iso-C16 BCFA was the most potent 
in the series and inhibited MCF-7 cell proliferation with an IC50 of ~ 80 µM, and potency 
decreased with an increase or decrease in chain length (IC50 concentrations from ~ 150 – 300 
µM) (Wongtangtintharn et al., 2004). Iso-BCFAs exhibit greater anticancer activity relative to 
their anteiso-counterparts. In a direct comparison, 13-MTD exerted greater anti-proliferative 
and pro-apoptotic effects than 12-MTA in MCF-7 cells (Vahmani et al., 2019). Similarly, Iso-
C17 inhibited MCF-7 cell proliferation with an IC50 of ~190 µM, whereas the anteiso-C17 
analogue only reduced cell growth to ~80% at the highest concentration tested (400 µM) 
(Vahmani et al., 2019; Wongtangtintharn et al., 2004). Methyl branching beyond the iso- and 
anteiso-positions, as well as multiple methyl branching groups, have also been explored, 
however cytotoxic activity against SK-BR-3 breast cancer cells remained modest (IC50 ~ 300-
350 µM) (Oku & Yanagita, 2009; Wongtangtintharn et al., 2006).  
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The SAR for BCFA anticancer activity is limited by the lack of structural diversity in 
the BCFAs tested to date.  All tested BCFAs possess methyl branching groups at various 
positions along saturated alkyl chains, and to our knowledge the effect of extended alkyl 
branching and unsaturation on anticancer activity has not been investigated. In this paper we 
report on the synthesis of a homologous series of saturated and unsaturated BCFAs, in which 
terminally branched methyl groups are replaced with ethyl, propyl and butyl moieties (Fig. 1). 
The anticancer activity of these new BCFAs were assessed against MCF-7, MDA-MB-231 and 
HeLa cancer cell lines and compared to 13-MTD, and the results were used to gain SAR 
insights that we anticipate will assist in the design of new and more potent BCFAs.  
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2. Material and Methods 
2.1 General Chemistry 
11-Bromoundecanoic acid was purchased from Fluorochem (Hadfield, Derbyshire, 
UK). All other reagents and anhydrous solvents were purchased from Sigma Aldrich (Castle 
Hill, NSW, Australia). Reactions were monitored by thin-layer chromatography (TLC) using 
silica gel 60 F254 plates. TLC plates were visualised with UV light and potassium permanganate 
TLC stain. Reaction products were purified by dry column vacuum chromatography with 
Merck silica gel 60H as the stationary phase in a 70mm (ID) x 60mm (h) column. 12 x 50mL 
fractions were collected using gradient elutions of hexane:DCM. The first fraction was 100:0 
and the percentage of DCM was increased by 5% increments to 50% DCM. 1H and 13C NMR 
spectra were recorded on an Agilent 500 MHz NMR. Spectra were referenced internally to 
residual solvent (CDCl3; 1H δ 7.26, 13C δ 77.10. DMSO-d6; 1H δ 2.49, 13C δ 39.52). High 
resolution mass spectra (HRMS) were recorded on an Agilent Technologies 6510 Q-TOF 
LCMS.  
Gas chromatography-mass spectrometry (GC-MS) was performed on a Shimadzu 
GCMS-QP2020 gas chromatograph-mass spectrometer fitted with an SH-Rxi-5Sil MS silica 
fused capillary column (30.0 m x 0.25 mm x 0.25 µm). Automated injections were performed 
on a Shimadzu AOC-20i auto injector. The injection port temperature was 280 °C and 1.0 µL 
injections were made in splitless mode with a purge time of 1 min. Helium was used as a carrier 
gas, at a flow rate of 1.42 mL/min. The column temperature was as follows: initial temperature 
of 40 °C for 2 min, then ramped at 6 °C/min to 320 °C, and held for 1 min. Eluted compounds 
were subjected to methane chemical ionisation and detection was made in full scan mode. 
The purity of all test compounds was confirmed by absolute quantitative NMR 
(qNMR). Briefly, DMSO-d6 was spiked with the internal calibrant (IC) 1,3,5-trioxane (99.5%) 
to give a final IC concentration of 2.92 mg/mL. Test compounds were accurately weighed on 
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a 5-decimal place analytical balance, dissolved in 600 µL of IC spiked DMSO-d6 and 
transferred to 5mm NMR tubes. 1H NMR spectra was recorded and the average integration of 
one proton from the IC and test compound was determined. The purity of the test compound 
(t) was then calculated using the following equation: 
 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑡𝑡 = 
𝐼𝐼𝐼𝐼𝑡𝑡𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑡𝑡 ×𝑀𝑀𝑀𝑀𝑡𝑡 ×𝑚𝑚𝐼𝐼𝑚𝑚𝑚𝑚𝑡𝑡
𝐼𝐼𝐼𝐼𝑡𝑡𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 × 𝑀𝑀𝑀𝑀𝐼𝐼𝐼𝐼 × 𝑚𝑚𝐼𝐼𝑚𝑚𝑚𝑚𝐼𝐼𝐼𝐼
 × 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝐼𝐼𝐼𝐼      
 
2.2 Methyl 11-bromoundecanoate (2) 
To a mixture of 1 (6.00 g, 22.63 mmol) in methanol (300 mL) was added AcCl (8.69 g, 113.13 
mmol). The resulting solution was left to stir at room temperature for 4 h. Excess methanol 
was removed under pressure and the residue was dissolved in DCM (80 mL). The organic 
phase was washed with saturated NaHCO3 in water (100 mL), water (100 mL) and brine (100 
mL) and dried over MgSO4. The solution was concentrated in vacuo affording methyl ester 2 
as a yellow oil (5.88 g, 93 %) that was used without further purification. HRMS (ESI) m/z 
[M+H]+ calcd for C12H23O2Br 279.0954; found 279.0946. 1H and 13C NMR spectra were in 
agreement with previously reported data (Jana et al., 2018). 
  
2.3 (11-methoxy-11-oxoundecyl)(triphenyl)phosphonium bromide (3) 
Ester 2 (5.88 g, 21.06 mmol) was left to stir with PPh3 (5.52 g, 21.06 mmol) at 140oC for 20 
hours. The resulting mixture was dissolved in DCM (5 mL) and cold diethyl ether (15 mL) was 
added to form a precipitate. The solid was collected by vacuum filtration and washed with cold 
diethyl ether (2 x 15 mL) and hexane (3 x 15 mL). The product was dried in vacuo, affording 
3 as a white solid (10.41 g, 91 %) that was used without further purification. Mp = 111-113oC. 
HRMS (ESI) m/z [M]+ calcd for C30H38O2P 461.2598; found 461.2599. 1H and 13C NMR 
spectra were in agreement with previously reported data (Dejarlais & Emken, 1978). 
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2.4 General synthesis of the monounsaturated methyl esters 5a-d 
To a suspension of 3 (1.500 g, 2.77 mmol) in anhydrous THF (10 mL) at 0oC under a nitrogen 
atmosphere was added NaN(TMS)2 (1.0 M in THF, 2.77 mmol). The resulting bright orange 
mixture was stirred for 20 minutes at room temperature. The reaction mixture was then cooled 
to -78oC, and the aldehyde (4a-d, 1.85 mmol) in THF (3 mL) was added dropwise. The mixture 
was stirred for 30 minutes at -78oC after which the reaction was allowed to warm to room 
temperature for two hours. After further stirring for two hours at room temperature the reaction 
was quenched with saturated aqueous NH4Cl (30 mL) and extracted with EtOAc (3 x 50 mL). 
The combined extracts were dried over MgSO4 and the EtOAc was removed in vacuo. The 
residue was purified on silica gel using a stepwise gradient elution with hexane:DCM (100:0 
to 50:50) to yield the unsaturated methyl esters 5a-d.  
 
2.4.1 Methyl (Z)-13-methyltetradec-11-enoate (5a) 
Yellow oil, yield = 42 %. 13C NMR (125 MHz, CDCl3) δ 174.31, 137.46, 127.46, 51.40, 34.09, 
29.88, 29.43, 29.39, 29.24, 29.22, 29.12, 27.27, 26.41, 24.93, 23.21. Z:E ratio = 97.8 : 2.2. 
HRMS (ESI) m/z [M+H]+ calcd for C16H31O2 255.2319; found 255.2318. The 1H spectrum was 
in agreement with previously reported data (Fogila and Vail, 1993). 
 
2.4.2 Methyl (Z)-13-ethylpentadec-11-enoate (5b) 
Yellow oil, yield = 75 %. 1H NMR (500 MHz, CDCl3) δ 5.39 (dt, J = 10.5, 2.5 Hz , 1H), 5.00 
(t, J = 7.5 Hz, 1H), 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.16-2.06 (m, 1H), 2.00 (q, J = 7.5 
Hz, 2H), 1.61 (quint, J = 7.5 Hz, 2H), 1.43-1.36 (m, 2H), 1.35-1.24 (m, 12H), 1.19-1.10 (m, 
2H), 0.82 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 174.32, 134.43, 130.04, 51.42, 
40.62, 34.10, 29.88, 29.44, 29.40, 29.30, 29.22, 29.13, 28.30, 27.68, 24.94, 11.86. Z:E ratio = 
100.0 : 0.0. HRMS (ESI) m/z [M+H]+ calcd for C18H35O2 283.2632; found 283.2634. 
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2.4.3 Methyl (Z)-13-propylhexadec-11-enoate (5c) 
Yellow oil, yield = 21 %. 1H NMR (500 MHz, CDCl3) δ 5.34 (dt, J = 10.5, 2.5 Hz, 1H), 5.01 
(t, J = 7.5 Hz, 1H), 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.00 (q, J = 7.5 Hz, 2H), 1.61 (quint, 
J = 7.5 Hz, 2H), 1.34-1.25 (m, 12H), 1.24-1.17 (m, 2H), 1.16-1.08 (m, 2H), 0.86 (t, J = 7.5 Hz, 
6H). 13C NMR (125 MHz, CDCl3) δ 174.33, 135.06, 129.47, 51.42, 38.26, 36.68, 34.11, 29.91, 
29.44, 29.40, 29.33, 29.23, 29.15, 27.69, 24.95, 20.45, 14.30. Z:E ratio = 100.0 : 0.0. HRMS 
(ESI) m/z [M+H]+ calcd for C20H39O2 311.2945; found 311.2947. 
 
2.4.4 Methyl (Z)-13-butylheptadec-11-enoate (5d) 
Yellow oil, yield = 43 %. 1H NMR (500 MHz, CDCl3) δ 5.34 (dt, J = 10.5, 2.5 Hz, 1H), 5.01 
(t, J = 7.5 Hz, 1H), 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.28-2.21 (m, 1H), 2.00 (q, J = 7.5 
Hz, 2H), 1.61 (quint, J = 7.5 Hz, 2H), 1.36-1.21 (m, 20H), 1.20-1.09 (m, 4H), 0.91-84 (m, 6H). 
13C NMR (125 MHz, CDCl3) δ 174.32, 135.18, 129.44, 51.42, 37.08, 35.68, 34.11, 29.90, 
29.62, 29.47, 29.41, 29.34, 29.24, 29.15, 27. 70, 24.95, 22. 92, 14.12. Z:E ratio = 99.7 : 0.3. 
HRMS (ESI) m/z [M+H]+ calcd for 339.3258; found 339.3255.  
 
2.4.5 Methyl (Z)-tetradec-11-enoate (5e) 
Yellow oil, yield: 86 %. 1H NMR (500 MHz, CDCl3) δ 5.39-5.31 (m, 2H), 3.66 (s, 3H), 2.30 
(t, J = 7.5 Hz, 2H), 2.06-1.99 (m, 4H), 1.62 (quint, J = 7 Hz, 2H), 1.37-1.25 (m, 12H), 0.95 (t, 
J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 175.83, 131.34, 128.85, 51.38, 33.98, 29.75, 
29.46, 29.35, 29.23, 29.22, 29.06, 27.02, 24.68, 20.55, 14.48. Z:E ratio = 100.0 : 0.0. HRMS 
(ESI) m/z [M+H]+ calcd for C15H28O2 241.2162; found 241.2168.  
 
2.5 General synthesis of the monounsaturated branched fatty acids 6a-d 
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To a solution of the unsaturated methyl ester (5a-d, 0.20 mmol) in EtOH (6 mL) was added 1.5 
M NaOH (8 mL). The reaction was heated to 40oC and stirred for four hours. The volume of 
the reaction mixture was reduced to 10 mL by rotary evaporation and the solution was adjusted 
to pH 1 with 1.0 M HCl. The solution was extracted with EtOAc (3 x 50 mL) and the combined 
extracts were dried over MgSO4. The EtOAc was removed in vacuo to afford unsaturated fatty 
acids 6a-d in high purity (>95%) without further purification. 
 
2.5.1 (Z)-13-methyltetradec-11-enoic acid (6a) 
Yellow oil, yield = 93%. 1H NMR (500 MHz, CDCl3) δ 5.25-5.15 (m, 2H), 2.61-2.54 (m, 2H), 
2.35 (t, J = 7.5 Hz, 2H), 2.01 (q, J = 7.5 Hz, 2H), 1.63 (quint, J = 7.5 Hz, 2H), 1.37-1.23 (m, 
12H), 0.94 (d, J = 7.0 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 179.65, 137.49, 127.46, 33.99, 
29.89, 29.44, 29.38, 29.24, 29.21, 29.04, 27.28, 26.42, 24.67, 23.22. FT-IR vmax (neat) 2923 
(O-H stretch), 2853 (C-H stretch), 1707 (C=O stretch), 1463 (C-H bend), 1411 (O-H bend), 
722 (C=C bend) cm-1. HRMS (ESI) m/z [M+H]+ calcd for C15H29O2 241.2162; found 241.2163. 
qNMR purity = 95%.  
 
2.5.2 (Z)-13-ethylpentadec-11-enoic acid (6b) 
Yellow oil, yield = 97%. 1H NMR (500 MHz, CDCl3) δ 5.40 (dt, J = 10.5, 2.5 Hz, 1H), 5.01 
(t, J = 7.5 Hz, 1H), 2.35 (t, J = 7.5 Hz, 2H), 2.16-2.07 (m, 1H), 2.01 (q, J = 7.5 Hz, 2H), 1.63 
(quint, J = 7.5 Hz, 2H), 1.44-1.37 (m, 2H), 1.37-1.21 (m, 12H), 1.20-1.09 (m, 2H), 0.83 (t, J = 
7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 178.74, 134.45, 130.06, 40.63, 33.82, 29.89, 29.69, 
29.45, 29.39, 29.32, 29.21, 29.05, 28.31, 27.69, 24.69. 22.69, 14.12, 11.87. FT-IR vmax (neat) 
2922 (O-H stretch), 2853 (C-H stretch), 1708 (C=O stretch), 1456 (C-H bend), 1412 (O-H 
bend), 723 (C=C bend) cm-1. HRMS (ESI) m/z [M+H]+ calcd for C17H33O2 269.2475; found 
269.2472. qNMR purity = 97%. 
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2.5.3 (Z)-13-propylhexadec-11-enoic acid (6c) 
Yellow oil, yield = 90%. 1H NMR (500 MHz, CDCl3) δ 5.34 (dt, J = 10.5, 2.5 Hz, 1H), 5.01 
(t, J = 7.5 Hz, 1H), 2.35 (t, J = 7.5 Hz, 2H), 2.33-2.27 (m, 1H), 2.01 (q, J = 7.5 Hz, 2H), 1.63 
(quint, J = 7.5 Hz, 2H), 1.39-1.25 (m, 16H), 1.24-1.19 (m, 2H), 1.18-1.09 (m, 2H), 0.86 (t, J = 
7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 179.17, 135.08, 129.47, 38.28, 36.69, 33.89, 29.92, 
29.70, 29.62, 29.51, 29.45, 29.40, 29.34, 29.22, 29.16, 29.07, 28.95, 27.71, 24.69, 20.46, 14.32. 
FT-IR vmax (neat) 2922 (O-H stretch), 2853 (C-H stretch), 1708 (C=O stretch), 1465 (C-H 
bend), 1413 (O-H bend), 722 (C=C bend) cm-1. HRMS (ESI) m/z [M+H]+ calcd for C19H37O2 
297.2788; found 297.2786. qNMR purity = 97%. 
 
2.5.4 (Z)-13-butylheptadec-11-enoic acid (6d) 
Yellow oil, yield = 81%. 1H NMR (500 MHz, CDCl3) δ 5.35 (dt, J = 10.5 Hz, 2.5 Hz, 1H), 
5.02 (t, J = 7.5 Hz, 1H), 2.35 (t, J = 7.5 Hz, 2H), 2.30-2.21 (m, 1H), 2.01 (q, J = 7.5 Hz, 2H), 
1.63 (quint, J = 7.5 Hz, 2H), 1.38-1.22 (m, 20H), 1.21-1.09 (m, 4H), 0.87 (t, J = 7.5 Hz, 6H). 
13C NMR (125 MHz, CDCl3) δ 179.34, 135.19, 129.44, 37.08, 35.68, 33.91, 29.89, 29.65, 
29.62, 29.47, 29.40, 29.34, 29.23, 29.06, 27.70, 24.67, 22.92, 14.12. FT-IR vmax (neat) 2922 
(O-H stretch), 2853 (C-H stretch), 1708 (C=O stretch), 1465 (C-H bend), 1411 (O-H bend), 
724 (C=C bend) cm-1. HRMS (ESI) m/z [M+H]+ calcd for C21H41O2 325.3101; found 325.3103. 
qNMR purity = 96 %. 
 
2.5.5 (Z)-tetradec-11-enoic acid (6e) 
Yellow oil, yield: 85%. HRMS (ESI) m/z [M+H]+ calcd for C14H26O2 227.2006; found 
227.2004. qNMR purity = 99 %. 1H and 13C NMR spectra were in agreement with previously 
reported data (Wube et al., 2011). 
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2.6 General synthesis of the saturated methyl esters 7a-d 
To a mixture of the monounsaturated methyl ester (5a-d, 0.65 mmol) in EtOH (10 mL) under 
a hydrogen atmosphere was added Pd/C (10 wt. %, 0.20 mmol). The suspension was stirred for 
20 hours at room temperature, after which the mixture was filtered over celite and washed with 
EtOH (2 x 25 mL). The EtOH was removed in vacuo and the residue was purified on silica gel 
with a stepwise gradient elution with hexane:DCM (100:0 to 50:50) to yield 7a-d.  
 
2.6.1 Methyl 13-methyltetradecanoate (7a) 
Yellow oil, yield = 87 %. 1H NMR (500 MHz, CDCl3) δ 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 
1.61 (quint, J = 7.5 Hz, 2H), 1.58-1.44 (m, 1H), 1.36-1.25 (m, 16H), 1.17-1.12 (m, 2H), 0.85 
(d, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 174.34, 51.42, 34.12, 29.92, 29.69, 29.63, 
29.58, 29.44, 29.25, 29.14, 27.96, 27.40, 24.95, 22.65. HRMS (ESI) m/z [M+H]+ calcd for 
C16H33O2 252.2475; found 252.2478.  
 
2.6.2 Methyl 13-ethylpentadecanoate (7b) 
Yellow oil, yield = 68 %. 1H NMR (500 MHz, CDCl3) δ 3.67 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 
1.61 (quint, J = 7.5 Hz, 2H), 1.35-1.19 (m, 21H), 1.18-1.11 (m, 2H), 0.83 (t, J = 7.5 Hz, 6H). 
13C NMR (125 MHz, CDCl3) δ 174.34, 51.41, 40.36, 34.11, 32.75, 30.13, 29.69, 29.64, 29.59, 
29.44, 29.25, 29.14, 26.76, 25.43, 24.95, 10.91. HRMS (ESI) m/z [M+H]+ calcd for C18H37O2 
285.2788; found 285.2787.  
 
2.6.3 Methyl 13-propylhexadecanoate (7c) 
Yellow oil, yield = 83 %. 1H NMR (500 MHz, CDCl3) δ 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 
1.61 (quint, J = 7.5 Hz, 2H), 1.28-1.15 (m, 27H), 0.87 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, 
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CDCl3) δ 174.34, 51.42, 36.94, 36.10, 34.12, 33.67, 30.15, 29.69, 29.65, 29.59, 29.44, 29.25, 
29.15, 26.67, 24.95, 19.79, 14.54. HRMS (ESI) m/z [M+H]+ calcd for C20H41O2 313.3101; 
found 313.3103.  
 
2.6.4 Methyl 13-butylheptadecanoate (7d) 
Yellow oil, yield = 44 %. 1H NMR (500 MHz, CDCl3) δ 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 
1.61 (quint, J = 7.5 Hz, 2H), 1.33-1.15 (m, 31H), 0.89 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, 
CDCl3) δ 174.32, 51.41, 37.34, 33.70, 33.38, 30.14, 29.69, 29.65, 29.59, 29.44, 29.25, 29.15, 
28.96, 26.70, 24.95, 23.16, 14.16. HRMS (ESI) m/z [M+H]+ calcd for C22H45O2 341.3414; 
found 341.3415. 
 
2.7 General procedure for synthesis of saturated branched fatty acids 8b-d 
To a mixture of the saturated methyl ester (7a-d, 0.20 mmol) in EtOH (6 mL) was added 1.5 
M NaOH (8 mL). The reaction was heated to 40oC and stirred for four hours. The volume of 
the reaction mixture was reduced to 10 mL by rotary evaporation and the solution was adjusted 
to pH 1 with 1.0 M HCl. The white solid was extracted with EtOAc (3 x 50 mL) and the 
combined extracts were dried over MgSO4. EtOAc was removed in vacuo to afford 13-MTD 
and 8b-d in high purity (>95%) without further purification. 
 
2.7.1 13-methyltetradecanoic acid (13-MTD) 
White solid, yield = 89%. Mp = 47-49oC (lit. Mp = 46.5-47 oC) (Shioiri et al., 1998). FT-IR, 
HRMS, 1H and 13C NMR spectra were in agreement with previously reported data (Khan et 
al., 2018). qNMR purity = 98%.   
 
2.7.2 13-ethylpentadecanoic acid (8b) 
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Yellow oil, yield = 96%. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.63 (quint, J 
= 7.5 Hz, 2H), 1.37-1.20 (m, 21H), 1.19-1.11 (m, 2H), 0.83 (t, J = 7.5 Hz, 6H). 13C NMR (125 
MHz, CDCl3) δ 178.57, 40.38, 33.79, 32.76, 30.13, 29.70, 29.65, 29.59, 29.43, 29.24, 29.06, 
26.77, 25.44, 24.69. FT-IR vmax (neat) 2922 (O-H stretch), 2853 (C-H stretch), 1708 (C=O 
stretch), 1460 (C-H bend), 1412 (O-H bend) cm-1.  HRMS (ESI) m/z [M+H]+ calcd for 
C17H35O2 271.2632; found 271.2635. qNMR purity = 96%. 
 
2.7.3 Characterization of 13-propylhexadecanoic acid (8c) 
Yellow oil, yield = 96%. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.63 (quint, J 
= 7.5 Hz, 2H), 1.40-1.17 (m, 27H), 0.87 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 
1.78.73, 36.94, 36.10, 33.81, 33.67, 30.14, 29.69, 29.65, 29.61, 29.58, 29.50, 29.42, 29.35, 
29.23, 29.15, 29.06, 29.67, 24.69, 19.80, 14.54. FT-IR vmax (neat) 2923 (O-H stretch), 2853 (C-
H stretch), 1710 (C=O stretch), 1465 (C-H bend), 1418 (O-H bend) cm-1. HRMS (ESI) m/z 
[M+H]+ calcd for C19H39O2 299.2945; found 299.2946. qNMR purity = 97%. 
 
2.7.4 Characterization of 13-butylheptadecanoic acid (8d) 
Yellow oil, yield = 89%. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.63 (quint, J 
= 7.5 Hz, 2H), 1.41-1.17 (m, 31H), 0.88 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 
178.77, 37.35, 33.81, 33.70, 33.38, 30.14, 29.69, 29.65, 29.58, 29.43, 29.32, 29.05, 28.96, 
26.70, 24.68, 23.16, 14.17. FT-IR vmax (neat) 2921 (O-H stretch), 2852 (C-H stretch), 1709 
(C=O stretch), 1465 (C-H bend), 1412 (O-H bend) cm-1. HRMS (ESI) m/z [M+H]+ calcd for 
C21H43O2 327.3258; found 327.3256. qNMR purity = 96%. 
 
2.8 General cell culture 
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Fetal bovine serum and trypsin/EDTA were purchased from (Invitrogen, Life Technologies, 
Victoria, Australia). Dulbecco's Modified Eagle Medium (DMEM), penicillin and 
streptomycin, phosphate-buffered saline (PBS), DMSO and general biochemicals were 
purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Human tumour cell lines were 
obtained from ATCC (Manassas, VA) and were grown at 37°C in a humidified atmosphere of 
5% CO2 in air in DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Confluent cells (80-90%) were harvested using Trypsin/EDTA after 
washing in PBS.  
 
2.9 Cell viability assay 
The anticancer activity of the synthesized compounds was determined using the MTS assay. 
Cells were seeded in 96-well plates (5×103 cells per well), 24 h later serum was removed and 
cells were treated with various concentrations of the test compounds, in DMSO (final 
concentration 0.1%), for 48 h. Control cells received serum-free DMEM and DMSO at 0.1%. 
Cell viability was determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, USA) according to the manufacturer’s recommendation. IC50 
values were defined as the drug concentration that prevented cell growth of more than 50% 
(relative to the vehicle control) and were determined using nonlinear regression analysis with 
Prism 7.0 (GraphPad Software, CA, USA). 
 
2.10 Statistical analysis 
For in vitro assays, data were analysed using one-way analysis of variance (ANOVA) followed 
by Tukey’s post hoc analysis. P<0.05 were accepted as being statistically significant. All 
statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software, 




Saturated (13-MTD and 8b-d) and unsaturated (6a-d) BCFAs were synthesised as 
shown in Scheme 1. In the first step the carboxylic acid group in bromo fatty acid 1 was ester-
protected using acetyl chloride and methanol. Under these mild reaction conditions acetyl 
chloride generates HCl in situ, which catalyses the esterification reaction. Methyl ester 2 was 
then reacted with triphenyl phosphine in a solvent-free melt to generate triphenylphosphonium 
bromide 3, which was then used in Wittig reactions with commercially available aldehydes 4a-
d to yield unsaturated branched fatty acid esters 5a-d with cis-double bonds in the Δ11 
positions. To produce the desired cis-olefins the Wittig reactions were conducted in THF at -
78 oC with sodium bis(trimethylsilyl)amide as the base. These reaction conditions were chosen 
because they have been shown to favour formation of cis-olefins (Z:E ratio ≥ 97:3) (Ainai et 
al., 2003; Ito et al, 2006; Rawling et al., 2010). To confirm that the Wittig reactions proceeded 
with the desired selectivity, the Z:E ratio of 5a-d was determined by GC-MS. The gas-
chromatograms of these compounds contained two peaks with identical mass spectra. Based 
on the elution order (Aro et al., 1998; Rawling et al., 2010), the first compounds to elute were 
identified as the trans-isomers (Rt ~ 31.88 min), which were baseline separated from the cis-
isomers (Rt ~ 31.98 min). The peak areas were then used to calculate the Z:E ratio, which in 
all cases exceed 97:3. 
Olefins 5a-d were then divided into two sets of aliquots, and alkaline hydrolysis of the 
ester groups in one of the sets afforded unsaturated BCFAs 6a-d (Fig. 1). The double bonds in 
the remaining 5a-d aliquots were reduced with palladium and hydrogen to give saturated 
BCFA esters 7a-d. Finally, removal of the ester protecting groups yielded BCFAs 13-MTD 




Scheme 1. Synthesis of the fatty acids 13-MTD 8b-d and 6a-e. Reagents and conditions (i) 
AcCl, methanol, rt, 4 hours; (ii) PPh3, 140 oC, 20 hours; (iii) NaN(TMS)2, THF, -78 oC to rt, 2 
hours; (iv)1.5M NaOH, ethanol, 40 oC, 4 hours; (v) Pd/C, hydrogen, rt, 20 hours. 
 
To assess the role of the methyl branching group and cis-Δ11 double bond in the 
anticancer activity of 6a, we also prepared the monounsaturated fatty acid (MUFA) 6e, which 
is the straight chain analogue of 6a. 6e was synthesised following the synthetic procedure 
outlined in Scheme 1. The Wittig reaction of phosphonium bromide 3 and straight chain 
aldehyde 4e affording the ester protect MUFA 5e with a cis-Δ11 double bond (Z:E ratio 
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confirmed by GC-MS analysis). Base-catalysed hydrolysis of the 5e with sodium hydroxide 
provided 6e in high purity.  
 
 
Fig. 1. Chemical structures of branched chain fatty acids used in this study. 
 
3.2  Cell culture conditions 
 
Prior to testing the all synthetic BCFAs against the full panel of cancer cell lines, we 
first developed assay conditions using 13-MTD, which is reported to reduce MCF-7 cell 
viability with IC50 concentrations of 10.03 μg/ml (~41 μM) and ~150 μM in media containing 
10% fetal bovine serum (FBS) (Wongtangtintharn et al., 2004; Yang et al., 2000). In our hands, 
13-MTD failed to affect MCF-7 cell viability at concentrations up to 500 μM after 72 hours 
under these conditions. The same result was found with 13-MTD synthesised by us or 
purchased commercially. One important difference between our assay conditions and those 
used for 13-MTD, and indeed all other previously reported anticancer BFCAs, was our choice 
of DMSO as the drug delivery vehicle rather than Tween 80 (Cai et al., 2013; Lin et al., 2012; 
Shioiri et al., 1998; Wongtangtintharn et al., 2006; Wongtangtintharn et al., 2005; 
Wongtangtintharn et al., 2004; Yang et al., 2000). Tween 80 has been shown to potentiate the 
in vitro effects of some anticancer agents by permeabilising the cell membrane (Riehm and 
Biedler, 1972), and it is possible Tween 80 also potentiates BFCA anticancer activity in vitro. 
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It is important to note that these observations do not invalidate the anticancer actions of 13-
MTD and other BCFAs, as indeed 13-MTD is active in vivo (Yang et al., 2000), however they 
do indicate that Tween 80 is not an ideal vehicle for in vitro anticancer assays. 
We next attempted cell viability assays with DMSO as vehicle but in serum free media 
(SFM), as SFM has been used previously in assessing the anticancer activity of the BCFA 12-
methyltetradecanoic acid (Yang et al., 2003). In SFM we found that 13-MTD significantly 
reduced MCF-7 cell viability at concentrations ≥ 100 μM (Fig 2a).  To confirm that the cells 
were viable and proliferative SFM we conducted cell counts from the time of serum withdrawal 
to the end of the 48 hour treatment period. We found that MCF-7 cell number increased 1.5 
fold over the treatment period. Similarly, the other two cell lines used in this study, MDA-MB-
231 and HeLa cells, grew 1.9 fold and 2.2 fold, respectively in SFM over 48 hours. Thus, all 
cell viability assays were performed in SFM for 48 hours with DMSO as delivery vehicle. 
 
3.3 In vitro anticancer activity 
 
The in vitro anticancer activities of the test fatty acids were first assessed against MCF-
7 cells. Dose-response curves were constructed (Fig 2) and IC50 concentrations were 
determined (Table 1). We also calculated Hill slopes (HS) and maximum effects (Emax) for 
each compound as these metrics can provide mechanistic information (Fallahi-Sichani et al., 
2013). 
In MCF-7 cells, 13-MTD was the most potent in the series of saturated BCFAs (13-
MTD, 8b-d) and reduced MCF-7 viability with an IC50 of 135 ± 13 µM (Table 1, Fig. 2a). IC50 
concentrations for the remaining saturated BCFAs were not able to be calculated due to 
limitations in the solubilities of these compounds at concentrations greater than 900 µM. From 
the dose-response curves obtained (Fig. 2b), the ethyl-branched analogue 8b displayed modest 
activity and was able to reduce MCF-7 cellular viability to 49 ± 7% at 900 µM. Propyl-
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branched BCFA 8c only affected cellular viability at 900 µM (76 ± 4%), and the butyl-branched 
analogue 8d did not affect cellular viability at any of the test concentrations.  
Unlike the saturated BCFAs 8b-d, all of the unsaturated BCFA’s 6a-d were active 
against MCF-7 cells. Although 6a-d reduced MCF-7 viability with similar IC50 values, the 
shapes of the dose-response curves revealed differences between these compounds (Fig. 2c). 
Methyl, ethyl and propyl branched compounds 6a-c displayed relatively steep dose-response 
curves with Hill slopes (HS) >2.8 and maximum effect (Emax) values of 0, reflecting the ability 
of 6a-c to completely abolish MCF-7 cell viability (Table 1). In contrast, the dose-response 
curve of the butyl-branched analogue 6d was shallow (HS = -1.6) and the cell viability did not 
drop below 32% as the concentration of 6d was increased from 150-450 μM (Emax = 0.3).  
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Table 1. IC50 concentrations, Hill Slopes (HS) and maximum effect (Emax) of fatty acids against the MCF-
7, MDA-MB-231 and HeLa cancer cell linesa 




[µM]  HS Emax 
IC50  
[µM]  HS Emax 
IC50  
[µM]  HS Emax 
13-MTD 135 ± 13 -3.1 0.0 Inactivec - - >900 - - 
8b >750 - - Inactivec - - >900 - - 
8c >900 - - Inactivec - - >900 - - 
8d >900 - - Inactivec - - >900 - - 
6a 49.4 ± 4.8 -6.4 0.0 534 ± 39 -2.6 0.0 80.7 ± 6.1 -1.5 0.0 
6b 58.9 ± 9.2 -3.2 0.0 Inactivec - - >900 - - 
6c 51.8 ± 6.1 -2.8 0.0 Inactivec - - >900 - - 
6d 47.6 ± 3.1 -1.6 0.3 Inactivec - - >900 - - 
6e 86.4 ± 9.3 -2.3 0.0 158 ± 42 -2.2 N/Ab 119 ± 13 -1.2 N/Ab 
a Cell viability was measured using the MTS assay after 48 h of treatment. 
b N/A: not applicable. Emax values for 6e in these cell lines could not be calculated because 6e was not soluble in 
cell media at concentration above 200 μM. 





Fig. 2. Dose-response curves showing the effects of synthetic BCFAs on the viability of MCF-
7 breast cancer cells after 48 h treatment. A) 13-MTD, B) saturated BCFAs 8b-d, C) 
unsaturated BCFAs 6a-d. Data represents the mean±SEM of at least 3 independent 




We also assessed the anticancer activity of the BCFAs against a wider panel of cancer 
cell lines (Table 1 and Fig. 3). In HeLa cervical cancer cells the unsaturated and methyl 
branched BCFA 6a was the most active in the series and reduced cell viability with an IC50 of 
80.7 ± 6.1 μM. All remaining BCFAs including 13-MTD were much less active that 6a and 
were only able to reduce cell viability to 70 – 90% of control at 900 μM (Fig S1 and Table S1 
in Supplementary Material).  
 
 
Fig. 3. Dose-response curves showing the effects of unsaturated BCFA 6a on the viability of 
MDA-MB-231 and HeLa cancer cells after 48 h treatment. Data represents the mean±SEM of 
at least 3 independent experiments.  
 
A similar pattern of activity emerged when the BFCAs were tested against MDA-MB-
231 breast cancer cells. Thus 6a fully abolished cell viability (Emax = 0) with an IC50 of 534 ± 
39 μM (Fig. 3) while 13-MTD and the other BCFAs had no effect on cell viability at 
concentrations up to 900 μM (Table S2 in Supplementary Material).   
MUFA 6e, the straight-chain analogue of 6a, was also assessed for anticancer activity 
in all three cell lines (Fig. 4). It was observed that 6e reduced the viability of all cell lines with 
IC50 concentrations ranging from 86 – 158 μM. Comparisons of the IC50 concentrations of 6a 
and 6e in each cell line revealed that 6a was approximately 1.5 - 2 fold more active that its 
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unbranched counterpart in MCF-7 and HeLa cells, while in MDA-MB-231 cells 6e was 3.4 
fold more active. Viability of MCF-7 cells was fully abolished by 6e (Emax = 0.0), however 
Emax values for 6e against MDA-MB-231 and HeLa cells could not be determined because 6e 
was not soluble in cell media at concentrations above 200 μM.  
  
  
Fig. 4. Dose-response curves showing the effects of MUFA 6e on the viability of MCF-7, 
MDA-MB-231 and HeLa cancer cells after 48 h treatment. Data represents the mean±SEM of 




The development of new anticancer drugs with novel mechanisms of action and low 
toxicity remains an ongoing need in cancer treatment. BCFAs are structurally distinct from 
current oncology drugs, well-tolerated in mice and inhibit tumour growth in vivo, and thus 
present an interesting opportunity for drug development (Murray et al., 2015). The precise 
cellular target/s of anticancer BCFAs are not known, and medicinal chemistry approaches to 
improve potency must rely on the synthesis and testing of BCFA analogues, and derivation of 
an SAR to guide drug design. To date, antiproliferative studies have exclusively examined 
saturated BCFAs with methyl branching-groups and reported gains in potency have been 
moderate (Wongtangtintharn et al., 2004). In considering this, we developed two homologous 
series of BCFAs based on the structure of 13-MTD- one fully saturated series, and a 
corresponding unsaturated series possessing cis-Δ11 double bonds- and assessed their 
anticancer activity against three cancer cell lines. 
 
4.1 Effects on MCF-7 cell viability 
13-MTD, a widely studied iso-BCFA, inhibits cell growth in various cancer cell lines 
both in vitro and in vivo (Cai et al., 2013; Lin et al., 2012; Wongtangtintharn et al., 2005; Yang 
et al., 2000). 13-MTD has previously been reported to reduce MCF-7 cell viability with an IC50 
concentrations of ~41 µM and ~150 µM (Wongtangtintharn et al, 2004), and using the assay 
conditions developed for this study we found similar levels of cytotoxicity (cf.  IC50 135 µM, 
Table 1). In contrast, 13-MTD was essentially inactive in both MDA-MB-231 and HeLa cells. 
Within the saturated series, 13-MTD was the only BCFA to significantly affect cellular 
viability at or below 300 µM. As the size of the branching group was increased to ethyl (8b) 
and propyl (8c) chains, the associated activity decreased (Fig. 2b). Indeed, the butyl-branched 
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analogue 8d was inactive at all test concentrations. These findings clearly illustrate a preference 
for smaller methyl-branching groups in saturated BCFAs.  
The unsaturated BCFAs 6a-d were all active and reduced MCF-7 viability. This activity 
pattern indicates that the activity of unsaturated BCFAs are not as sensitive to branching group 
size as their saturated counterparts. Interestingly, while 6a-d displayed similar IC50 
concentrations, differences in the dose-response curve of butyl-branched 6d were observed. 
The HS values for 6a-d were within the range reported for a wide panel of anticancer drugs 
against MCF-7 cells (Fallahi-Sichani et al., 2013), however 6d had a relatively low HS and 
high Emax relative to 6a-c. We saw no evidence that the high Emax value of 6d resulted from 
precipitation in the assays. Indeed, similar shallow dose-response curves with Emax values > 0 
have been reported for the clinical anticancer drugs docetaxel and geldanamycin in cell 
viability assays using the MCF-7 cell line (Fallahi-Sichani et al., 2013). Thus, the differences 
in HS and Emax values calculated for 6d suggest that 6d reduces MCF-7 cell viability by a 
different mechanism of action to 6a-c (Fallahi-Sichani et al., 2013),  which may arise from the 
increased bulk provided by the butyl branching-group in 6d causing it to interact with different 
cellular target/s to that of 6a-c. Follow-up mechanistic studies could assess the ability of 6a-d 
to inhibit COX-2 activity as MUFAs with anticancer activity have been shown to reduce COX-
2 mediated prostaglandin E2 (PGE2) synthesis (Cui et al., 2012).  
 
4.2 Effects on MDA-MB-231 and HeLa cell viability 
13-MTD has been shown to reduce the viability of over 10 cancer cell lines, however 
the anticancer activity of 13-MTD and other BCFAs has not been studied using MDA-MB-231 
and HeLa cancer cell lines. In this study we found that these two cell lines are much more 
resistant than MCF-7 cells to BCFA anticancer activity. 13-MTD was essentially inactive 
against both cell lines, and this lack of activity was also observed for all saturated BCFAs (8b-
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d) and unsatutared BCFAs 6b-d. The only exception was the unsaturated and methyl-branched 
BCFA 6a, which was active across all three cell lines. Comparison of the IC50 concentrations 
showed that MCF-7 cells were most sensitive to 6a, followed by HeLa and then MDA-MB-
231 cells. Consistent with this pattern of activity, HeLa cell viability was moderately reduced 
by the remaining BCFAs at 900 μM, while MDA-MB-231 cells were unaffected at all test 
concentrations. 
 
4.3 Effect of fatty acid branching on anticancer activity- comparison of 6a and 6e 
Cell testing revealed that 6a is one of the most potent BCFAs reported to date, and 
almost 3-fold more potent that it’s saturated counterpart 13-MTD. Furthermore, within the 
series 6a was the only BCFA that was active against all cell lines tested. These results indicate 
that inclusion of a cis-Δ11 double bond into the BCFA scaffold greatly increases anticancer 
activity. However an important SAR consideration is whether the superior activity of 6a is 
dependent on the both the methyl branching group and the cis-Δ11 double bond, or the double 
bond only, because several straight chain MUFAs have been reported to reduce the viability of 
breast cancer cell lines (Cui et al., 2012; Miller et al, 2003). We therefore synthesised MUFA 
6e, the unbranched analogue of 6a and compared their activities. In MDA-MB-231 cells, which 
were largely unaffected by the BCFAs, 6e was more potent than 6a. However in MCF-7 and 
HeLa cells, the two cell lines that were more susceptible to BCFAs, the IC50 concentrations of 
6a was 1.5 - 2 fold lower than that of 6e, which confirmed that both the branching group and 
cis-Δ11 double bond are critical to activity in these cell lines. Collectively, these findings 
indicate that unsaturation is an effective strategy to increase the potency of BCFAs, although 




By synthesising a homologous series of saturated and unsaturated BCFAs and 
evaluating their effects on the viability of MCF-7, MDA-MB-231 and HeLa cells, we have 
been able to expand the structure-activity relationship governing BCFA anticancer activity. In 
general MCF-7 cells were the most susceptible to the anticancer actions of the BCFAs tested, 
followed by HeLa and then MDA-MB-231 cells. It was shown that symmetrically extending 
the branching chains of saturated BCFAs is detrimental to activity in MCF-7 cells. In contrast, 
inclusion of a cis-Δ11 double bond into the BCFA chain improves activity relative to their 
corresponding fully saturated analogues and unsaturated BCFA 6a was active across all the 
cell lines tested. These new SAR insights may assist in the development of new and more 
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